SEPRACOR DOUBLES Q1 REVENUE, TURNS PROFIT

Sepracor Inc. — driven by booming sales of its anti-insomnia drug Lunesta — turned a profit in its fiscal 2006 first quarter and more than doubled revenue compared to the same period last year. The Marlborough, Mass., pharmaceutical company (Nasdaq: SEPR) reported $285.7 million in revenue for the quarter ending March 31, compared to $119 million in revenue in the fiscal 2005 first quarter, just before Lunesta sales launched.
Boston Business Journal